rethinkTHC Search
Menu
Study breakdown

The Most Detailed Look Yet at What Cannabis Smoking Does to the Lungs

Cross SectionalModerate evidence
The takeaway

A Canadian study combining CT scans, xenon MRI, lung function tests, and airway cell analysis found that heavy cannabis smokers had worse respiratory symptoms, lower lung function, and overproduction of mucus-related genes.

Anyone who smokes cannabis regularly, pulmonologists, respiratory researchers studying non-tobacco inhalation exposures.

What the researchers found

The CANUCK study examined 139 cannabis smokers (categorized by joint-year exposure: low ≤5, moderate 5–20, high >20 joint-years) alongside 57 never-smokers, using an unusually comprehensive battery of tests.

Cannabis smokers at all exposure levels reported worse respiratory symptoms than never-smokers. High joint-year smokers showed lower pre-bronchodilator FEV1 — the standard measure of airflow obstruction — suggesting measurable lung function decline with heavy, long-term use.

The study went beyond standard pulmonary testing. Hyperpolarized xenon-129 MRI revealed ventilation abnormalities, and chest CT showed structural changes. At the cellular level, airway epithelial brushings from bronchoscopy demonstrated upregulation of immune response signatures and mucin genes. Air-liquid interface cell cultures confirmed elevated MUC5AC protein — a mucus component associated with airway disease — and its expression correlated with clinical symptoms.

A notable complication: 84% of cannabis-smoking participants reported current or former cigarette smoking or vaping, making it difficult to isolate cannabis-specific effects from tobacco co-exposure.

Why it matters

This is one of the most methodologically comprehensive studies of cannabis smoking's respiratory effects. Most prior research relied on questionnaires and basic spirometry. By adding advanced imaging (xenon MRI), cellular analysis (bronchoscopic brushings), and molecular data (gene expression, protein quantification), the CANUCK study provides multiple converging lines of evidence that cannabis smoking affects the airways at structural, functional, and molecular levels.

The numbers in context

139 cannabis smokers, 57 never-smokers. Exposure groups: ≤5, 5–20, >20 joint-years. 48% male, median age 27. 84% reported concurrent cigarette/vaping history. High-exposure group showed lower pre-bronchodilator FEV1. Elevated MUC5AC protein in airway cultures correlated with symptoms.

How the study worked

Cross-sectional study of 139 cannabis smokers and 57 never-smokers. Multi-modal assessment: respiratory symptom questionnaires, spirometry, chest CT, hyperpolarized xenon-129 MRI, bronchoscopic airway epithelial brushings with transcriptomic analysis, and air-liquid interface cell cultures for MUC5AC protein quantification.

Who was studied

N=196 participants (139 cannabis smokers, 57 never-smokers), median age 27 years, Canada.

What this study cannot tell us

Cross-sectional design cannot establish causation or track progression over time. The 84% tobacco/vaping co-use rate makes it difficult to attribute findings specifically to cannabis. Participants were relatively young (median 27), so long-term consequences may not yet be manifest. The study recruited from a single Canadian center, limiting generalizability.

How to read the evidence

Cross-sectional study with exceptionally comprehensive methodology (CT, xenon MRI, bronchoscopy, transcriptomics) — strong multi-modal evidence but limited by cross-sectional design and high co-use rates.

When this study was published

Published in 2026 in the European Respiratory Journal, enabled by Canada's cannabis legalization and representing the current frontier of cannabis respiratory research.

The bigger picture

The respiratory effects of cannabis smoking have been studied less rigorously than tobacco, partly because cannabis was illegal in most research settings until recently. Canada's 2018 legalization enabled studies like CANUCK. The finding that mucin gene upregulation and MUC5AC overproduction occur in cannabis smokers echoes pathways well-established in tobacco-related COPD — raising the question of whether heavy cannabis smoking could follow a similar trajectory to chronic lung disease. The smoking-versus-vaping comparison (RTHC-00231) and the cardiovascular data (RTHC-00237) add additional dimensions to the inhalation risk picture.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

  • Do the molecular changes in airway cells progress to clinically significant COPD with continued cannabis smoking? Would exclusive cannabis smokers (without tobacco history) show the same patterns? Does switching from smoking to vaping cannabis reverse the mucin gene upregulation?

Read the original research

Clinical, physiological, imaging and molecular responses to cannabis smoking: the Canadian Users of Cannabis Smoke (CANUCK) study.

The European respiratory journal, 67(1)

The European Respiratory Journal is a well-respected journal focusing on respiratory medicine.

Citation

Leung, Clarus; Gilchrist, Cassie L; Wang, Carolyn J; Liggins, James A; Li, Xuan; Yang, Julia; Cheung, Chung Y; Gerayeli, Firoozeh V; Singhera, Gurpreet K; Hsu, Wu Jih; Lidher, Lavraj S; Moo, Karolina; Leyson, Eleazar; Dhillon, Satvir S; Shaipanich, Tawimas; Leipsic, Jonathon A; Guenette, Jordan A; Rayment, Jonathan H; Kirby, Miranda; Gershon, Andrea S; Sadatsafavi, Mohsen; Tan, Wan C; Parraga, Grace; Carlsten, Christopher; Eddy, Rachel L; Sin, Don D; Leung, Janice M. (2026). Clinical, physiological, imaging and molecular responses to cannabis smoking: the Canadian Users of Cannabis Smoke (CANUCK) study.. The European respiratory journal, 67(1). https://doi.org/10.1183/13993003.01659-2025

Explore the wider topic